319 related articles for article (PubMed ID: 32529951)
1. A new treatment of alopecia induced by palbociclib: Topical cetirizine.
Caro G; Fortuna MC; Magri F; Federico A; Carlesimo M; Rossi A
J Oncol Pharm Pract; 2021 Mar; 27(2):460-463. PubMed ID: 32529951
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
Guillemois S; Patsouris A; Peyraga G; Chassain K; Le Corre Y; Campone M; Augereau P
Clin Breast Cancer; 2018 Oct; 18(5):e755-e758. PubMed ID: 30120047
[No Abstract] [Full Text] [Related]
4. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia.
Rossi A; Campo D; Fortuna MC; Garelli V; Pranteda G; De Vita G; Sorriso-Valvo L; Di Nunno D; Carlesimo M
J Dermatolog Treat; 2018 Mar; 29(2):149-151. PubMed ID: 28604133
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
7. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib-Induced Posterior Reversible Encephalopathy Syndrome: A Previously Unreported Toxicity.
Harrold EC; Peters NM; Williams LJ; Sui JS; McCaffrey JA
J Oncol Pract; 2019 Feb; 15(2):119-121. PubMed ID: 30763200
[No Abstract] [Full Text] [Related]
9. A case of discoid lupus erythematosus because of palbociclib.
Calabrese G; Licata G; Gambardella A; De Rosa A; Ronchi A; Argenziano G
J Cutan Pathol; 2020 Jul; 47(7):668-670. PubMed ID: 32222999
[No Abstract] [Full Text] [Related]
10. Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Anampa J; Haque T; Murakhovskaya I; Wang Y; Bachiashvili K; Papazoglu C; Pradhan K; Steidl UG; Sparano JA; Verma A
Haematologica; 2018 Mar; 103(3):e98-e102. PubMed ID: 29191840
[No Abstract] [Full Text] [Related]
11. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
13. A case of delayed-onset scarring alopecia in a 75-year-old woman.
Maguire M; Drumm C; Woods G; Mullally W; Redmond M; Grogan L; O'Kane M
Clin Exp Dermatol; 2020 Aug; 45(6):768-770. PubMed ID: 32369207
[No Abstract] [Full Text] [Related]
14. Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications.
Santoni M; Occhipinti G; Romagnoli E; Miccini F; Scoccia L; Giulietti M; Principato G; Saladino T; Piva F; Battelli N
BioDrugs; 2019 Dec; 33(6):613-620. PubMed ID: 31529317
[TBL] [Abstract][Full Text] [Related]
15. Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
Nasir UM; Mozeika AM; Sayan M; Jan I; Kowal N; Haffty B; Ahlawat S; Kothari N
Anticancer Res; 2020 Sep; 40(9):5291-5294. PubMed ID: 32878819
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
17. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.
Ban M; Miše BP; Majić A; Dražić I; Vrdoljak E
Future Oncol; 2018 Mar; 14(6):537-544. PubMed ID: 29164917
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical development of palbociclib and future perspectives.
de Dueñas EM; Gavila-Gregori J; Olmos-Antón S; Santaballa-Bertrán A; Lluch-Hernández A; Espinal-Domínguez EJ; Rivero-Silva M; Llombart-Cussac A
Clin Transl Oncol; 2018 Sep; 20(9):1136-1144. PubMed ID: 29564714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
